Overview

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Status:
Not yet recruiting
Trial end date:
2029-07-05
Target enrollment:
Participant gender:
Summary
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Cincinnati
Treatments:
Capecitabine
Mitomycin
Mitomycins